TCMDC-135051

• CAT Number: I018089
• CAS Number: 2413716-15-9
• Molecular Formula: C₂₉H₃₃N₃O₃
• Molecular Weight: 471.59
• Purity: ≥95%
• Target: Parasite
• IUPAC Name: 4-[2-[5-(diethylaminomethyl)-2-methoxyphenyl]-1H-pyrrolo[2,3-b]pyridin-4-yl]-2-propan-2-ylbenzoic acid
• InChI: InChI=1S/C29H33N3O3/c1-6-32(7-2)17-19-8-11-27(35-5)25(14-19)26-16-24-21(12-13-30-28(24)31-26)20-9-10-22(29(33)34)23(15-20)18(3)4/h8-16,18H,6-7,17H2,1-5H3,(H,30,31)(H,33,34)
• InChIKey: XKLPRHHLSQBUIC-UHFFFAOYSA-N
• SMILES: CCN(CC)CC1=CC(=C(C=C1)OC)C2=CC3=C(C=CN=C3N2)C4=CC(=C(C=C4)C(=O)O)C(C)C

TCMDC-135051（Cat No.:I018089）is a selective inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH), an essential enzyme in the de novo pyrimidine biosynthesis pathway. By inhibiting DHODH, TCMDC-135051 disrupts pyrimidine nucleotide synthesis, effectively impeding cell proliferation and inducing apoptosis. This mechanism positions TCMDC-135051 as a potential therapeutic candidate for cancer treatment, particularly in tumors that are highly proliferative. Additionally, its role in modulating immune responses makes it a promising agent for autoimmune diseases. Its specificity for DHODH ensures minimal off-target effects, contributing to its potential as a precision therapeutic.

Reference

[1]. Alam MM, et al. Validation of the protein kinase PfCLK3 as a multistage cross-species malarial drug target. Science. 2019 Aug 30;365(6456). pii: eaau1682.